Diabetes Mellitus, Type 2 | Examining Genetic Influence on Response to Beta-Blocker Medications in People With Type 2 Diabetes

Diabetes Mellitus, Type 2 research study

What is the primary objective of this study?

Beta-blockers are medications used to treat cardiovascular disease (CVD) symptoms, including high blood pressure and chest pain. People with diabetes who receive beta-blockers may experience adverse health effects, but the exact cause of why this happens remains unknown. This study will examine the genetic factors that may influence how atenolol, a beta-blocker medication, affects fat breakdown, blood sugar levels, and heart function in people with type 2 diabetes.

Who is eligible to participate?

Inclusion Criteria: - Type 2 diabetes - Pre-Diabetes Exclusion Criteria: - Insulin therapy - Treatment with any beta-blocker in the 30 days before study entry - Asthma - Chronic obstructive pulmonary disease (COPD) - Greater than first degree heart block - Heart rate less than 60 bpm - Systolic blood pressure less than 90 mm Hg - Raynaud's phenomenon - Known history of angina, heart attack, heart failure, coronary revascularization, or automatic implantable cardioverter defibrillators - Pregnant - Creatinine clearance less than 35 ml/min - Hematologic dysfunction (white blood cell [WBC] count less than 3000 or hematocrit less than 28%) - Allergy to amide anesthetics

Which medical condition, disease, disorder, syndrome, illness, or injury is researched?

Diabetes Mellitus, Type 2

Study Interventions

Interventions can include giving participants drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available or noninvasive approaches such as surveys, education, and interviews.

Drug:Atenolol12.5 mg twice daily of atenolol for 1 week; increased to 25 mg twice daily for a total of 8 weeks, if the medication is well tolerated

Study Arms

Research studies and clinical trials typically have two or more research arms. An arm is a group of people who receive the same treatment in the study.

AtenololParticipants will receive atenolol for 8 weeks.

Study Status


Start Date: December 2009

Completed Date: May 2014

Phase: Phase 4

Type: Interventional


Primary Outcome: Change in Diastolic Function (Annular Tissue Velocity [Em])

Secondary Outcome: Change in Triglycerides

Study sponsors, principal investigator, and references

Principal Investigator: Amber L. Beitelshees, PharmD, MPH

Lead Sponsor: University of Maryland

Collaborator: National Heart, Lung, and Blood Institute (NHLBI)

More information:

Discuss Atenolol